Business Wire

NV-UECTEL-WIRELESS

10.1.2024 18:01:36 CET | Business Wire | Press release

Share
Quectel and Morse Micro Introduce the Industry’s First Wi-Fi HaLow Module to Achieve European CE and US FCC Certifications at CES 2024

CES 2024 – Quectel Wireless Solutions, a global IoT solutions provider, and Morse Micro, the leading Wi-Fi HaLow silicon vendor, today announced that the Quectel FGH100M Wi-Fi HaLow module has received CE certification for Europe and Federal Communications Commission (FCC) certification for the US. The CE and FCC certification of the module, powered by Morse Micro’s MM6108 SoC, underscores the rigorous testing and compliance with the highest standards of safety, health, and environmental protection required in the European Area, while the certification by the FCC also means that the module is approved for use in electronic devices sold in the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110233128/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel and Morse Micro Introduce the Industry’s First Wi-Fi HaLow Module to Achieve European CE and US FCC Certifications at CES 2024 (Photo: Business Wire)

The certification represents a crucial step in expanding the market reach of Wi-Fi HaLow technology and enabling its deployment in a wide range of Wi-Fi HaLow and IoT applications across multiple geographic regions. This industry first achievement not only underscores Wi-Fi HaLow technology’s readiness for the global market, but also solidifies the protocol’s position as a leading communications standard.

"Wi-Fi HaLow technology represents the future of global connectivity, and receiving both the CE mark and FCC certification is a testament to the reliability, safety, and interoperability Wi-Fi HaLow modules," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our collaboration with Morse Micro has been crucial in achieving this milestone and other industry certifications."

The Wi-Fi HaLow module is designed for extended range and lower power consumption, making it ideal for numerous IoT applications, from smart homes and industrial automation to agricultural technology and beyond. With this certification, Quectel and Morse Micro are poised to lead the charge in long-range, low-power IoT connectivity, offering best-in-class Wi-Fi CERTIFIED HaLow solutions that meet the demands of today’s connected world.

"The Morse Micro team has been working tirelessly this year to expand the global reach of our Wi-Fi HaLow solutions, and that day has finally come with the achievement of CE certification for our module products,” said Prakash Guda, Vice President of Marketing and Product Management at Morse Micro. "By securing European CE certification for Wi-Fi HaLow modules, Quectel and Morse Micro have demonstrated the standard’s global acceptance. It’s a major leap forward in establishing Wi-Fi HaLow as a universal standard for IoT and wireless connectivity."

Operating in the sub-GHz frequency band, the Wi-Fi HaLow 802.11ah standard was designed from the ground up for the IoT, offering an optimal combination of extended range, power efficiency, long battery life for wireless devices, superior penetration of barriers, large network capacity, advanced security, and Wi-Fi compatibility.

Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle

Quectel offers a range of antennas for the FGH100M LoRa module, including the YCIS001AA, YCIS002AA, YCIS003AA, YFNP017WWA, YPCS002BA, YMCP003AA, YEIN002AA, YECN028AA and YECW000N1A, enabling flexibility and compatibility to meet diverse project requirements.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

About Morse Micro

Morse Micro is a leading Wi-Fi HaLow fabless semiconductor company based in Sydney, with global offices. As the world's premier Wi-Fi HaLow company, we pioneer next-gen IoT wireless connectivity solutions. Morse Micro is now sampling its Wi-Fi Alliance and FCC-certifiable MM6108 production silicon: the fastest, smallest, lowest power and longest-range Wi-Fi HaLow chip available in the market. Learn more at https://www.morsemicro.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240110233128/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye